Abstract

COMPARATIVE STUDY OF THE TOXICITY PROFILE IN PATIENTS RECEIVING CISPLATIN-PACLITAXEL VS CARBOPLATINPACLITAXEL IN OVARIAN CANCER

Neeraj Kumar*, Harshita Singh, Ashok Kumar Gupta, Amit Singh and Neeraj Fuloria

Abstract

Background: The standard chemotherapy for ovarian cancer includes the combination of paclitaxel and a platinum compound. Comparing cisplatin and paclitaxel, with carboplatin and paclitaxel, it has been found that substitution of the analog carboplatin for cisplatin in this combination may improve the toxicity profile. Methodology: 40 patients diagnosed with advanced epithelial ovarian cancer (stage III and stage IV), were recruited for the study and were divided into two groups. One group received cisplatin-paclitaxel and the other received carboplatin-paclitaxel. Results: Hematological toxicity namely decrease RBC, WBC, PLT, Hb and renal parameters urea creatinine, GFR decreases in cisplatin group.

Keywords: Ovarian cancer, Nephrotoxicity, Hematological toxicity, Cisplatin, Carboplatin.